Get started
Author

Guorong Zou

Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
2024 · Xu Liu, Yuan Zhang, et al. · The Lancet · 218
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
2020 · Chunyan Lan, Jingxian Shen, et al. · Journal of Clinical Oncology · 217
PDF
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial
2025 · Ye-Lin Liang, Xu Liu, et al. · JAMA · 93
Fully-Automated Segmentation of Nasopharyngeal Carcinoma on Dual-Sequence MRI Using Convolutional Neural Networks
2020 · Yufeng Ye, Zongyou Cai, et al. · Frontiers in Oncology · 47
PDF
Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial
2025 · The DIAMOND Study Group, Cheng Xu, et al. · JAMA · 39
Systemic longitudinal immune profiling identifies proliferating Treg cells as predictors of immunotherapy benefit: biomarker analysis from the phase 3 CONTINUUM and DIPPER trials
2024 · Sai-Wei Huang, Wei Jiang, et al. · Signal Transduction and Targeted Therapy · 30
PDF
Long‐term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study
2024 · Chunyan Lan, Huaiwu Lu, et al. · 癌症：英文版 · 28
Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study
2024 · Xiaozhong Chen, Wei Wang, et al. · Signal Transduction and Targeted Therapy · 26
Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.
2024 · Jun Ma, Ying Sun, et al. · Journal of Clinical Oncology · 20
Efficacy and safety of sintilimab plus albumin-bound-paclitaxel in recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II trial
2023 · Yin Wang, Jing Zhao, et al. · EClinicalMedicine · 20
PDF
Efficiency and toxicity of nab-paclitaxel and camrelizumab in the second or above line treatment of advanced non-small cell lung cancer: a retrospective cohort study
2023 · Chen Yin, Guo-Rong Zou, et al. · Journal of Thoracic Disease · 18
PDF
PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM).
2023 · Jun Ma, Ying Sun, et al. · Journal of Clinical Oncology · 17
Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase III MECCA Trial
2025 · Ruo-Xi Hong, Fei Xu, et al. · Journal of Clinical Oncology · 16
Brain and frontal‐bone metastasis from nasopharyngeal carcinoma: Case report and literature review
2019 · Zhen Su, Xiaolong Cao, et al. · Head & Neck · 15
Prognostic impact of family history of cancer in Southern Chinese patients with esophageal squamous cell cancer
2019 · Zhen Su, Guo-Rong Zou, et al. · Journal of Cancer · 12
PDF
Current Smoking has a Detrimental Effect on Survival for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) negative Advanced non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Treated with Pemetrexed Continuation Maintenance
2018 · Liping Lin, Juanjuan Zhao, et al. · Journal of Cancer · 12
PDF
Platycodon D reduces obesity and non-alcoholic fatty liver disease induced by a high-fat diet through inhibiting intestinal fat absorption
2024 · Xingkui Tang, Yi Yang, et al. · Frontiers in Pharmacology · 10
PDF
Supraglottic squamous cell carcinomas have distinctive clinical features and prognosis based on subregion
2017 · Weiquan Ding, Tianrun Liu, et al. · PLoS ONE · 10
PDF
Treatment options for recurrent platinum-resistant ovarian cancer: A systematic review and Bayesian network meta-analysis based on RCTs
2023 · Juan Li, Guorong Zou, et al. · Frontiers in Oncology · 9
Prognostic impact of cigarette smoking on the survival of patients with established esophageal squamous cell carcinoma receiving radiotherapy: A retrospective study from southern China
2019 · Guo‑Rong Zou, Zhen Su, et al. · Experimental and Therapeutic Medicine · 8
PDF
[Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma].
2009 · Fang-Yun Xie, Guo-Rong Zou, et al. · PubMed · 8
Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy for nasopharyngeal carcinoma: a systematic review and pooled analysis
2021 · Jie Tang, Guo-Rong Zou, et al. · Journal of Cancer · 7
PDF
804 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy
2020 · Xiaozhong Chen, Wei Wang, et al. · Journal for ImmunoTherapy of Cancer · 7
909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results
2021 · X. Chen, C. Hu, et al. · Annals of Oncology · 6
Combined pyrotinib and fulvestrant for hormone receptor‐positive and HER2‐positive metastatic breast cancer: A multicenter, single‐arm, phase II trial
2024 · Jianli Zhao, Yunfang Yu, et al. · MedComm · 5
PDF
Works count: 54
Citation count: 931
H-index: 14
I10-index: 18
Year
Topic
Type